Turning fat into muscle: can this be an alternative to anti‐obesity drugs such as semaglutide?

Wackerhage, Henning; Hinrichs, Arne; Wolf, Eckhard; Hrabě de Angelis, Martin

doi:10.1113/jp286430

The Journal of Physiology

2024

DOI: 10.1113/jp286430

|View full text |Cite

Turning fat into muscle: can this be an alternative to anti‐obesity drugs such as semaglutide?

Henning Wackerhage,

Arne Hinrichs,

Eckhard Wolf

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Gross,

Brinkmann

2024

Front. Endocrinol.

View full text Add to dashboard Cite

Modern incretin mimetics are a hot topic in the treatment of adults with obesity or overweight (1). Weekly subcutaneous injections of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs have been shown to elicit weight reductions of up to 15-20% in adults with obesity or overweight (2, 3)levels of weight loss previously reported only after bariatric surgery. The effects of GLP-1 RAs are manifold: they increase postprandial insulin secretion from pancreatic b-cells, suppress glucagon secretion from a-cells, slow gastric emptying, and reduce appetite. The suppression of appetite under GLP-1 RA treatment is presumably induced by actions on peripheral vagal nerve endings in the gut mucosa that project into the central nervous system, engaging satiation signals. Whether and how incretin mimetics can access central brain targets relevant for appetite suppression is a subject of current debate (4). While the precise mechanisms behind the hypophagic effects of GLP-1 RAs are still not fully understood, GLP-1 RAs like liraglutide or semaglutide, as well as tirzepatide, a GLP-1/GIP RA, have been authorized for weight loss as an adjunct therapy to lifestyle interventions in adults with obesity (body mass index (BMI) of ≥ 30 mg/m²) or adults with overweight (BMI ≥ 27 mg/m² but ≤ 30 mg/m²) who have at least one weight-related health problem. However, in practice, diet and exercise may risk being overshadowed by what has been described as a "miracle drug" in public media. Here, we present some reasons why regular exercise is crucial during and after incretin-based pharmacotherapy for people who want to lose weight.

show abstract

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Gross,

Brinkmann

2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Turning fat into muscle: can this be an alternative to anti‐obesity drugs such as semaglutide?

Cited by 1 publication

References 17 publications

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Contact Info

Product

Resources

About